CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides

Molecular Pharmacology

Volumn 58, Issue 2, 2000, Pages 399-406

  Bläker, Michael ^a,b   Ren, Yong ^a   Seshadri, Lakshmi ^a   McBride, Edward W ^a   Beinborn, Martin ^a   Kopin, Alan S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GASTRIN RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; GASTROINTESTINAL DISEASE; GENE MUTATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL;

EID: 0343192441     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.2.399     Document Type: Article

References (41)

1. Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12:1693-1703.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein coupled receptors. Methods Neurosci 25:366-428.
3. Beinborn M, Lee YM, McBride EW, Quinn SM and Kopin AS (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature (Lond) 362:348-350.
4. Beinborn M, Quinn SM and Kopin AS (1998) Minor modifications of a cholecystokinin B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. J Biol Chem 273:14146-14151.
5. Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M and Kopin AS (1998) Mutations within the CCK-B/gastrin receptor ligand 'pocket' interconvert the function of non-peptide agonists and antagonists. Mol Pharmacol 54:857-863.
6. Caron MG and Lefkowitz RJ (1993) Catecholamine receptors: Structure, function, and regulation. Recent Prog Horm Res 48:277-290.
7. Cascieri MA, Fong TM and Strader CD (1995) Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. J Pharmacol Toxicol Methods 33:179-185.
8. Faris PL, Komisaruk BR, Watkins LR and Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science (Wash DC) 219:310-312.
9. Fu D, Ballesteros JA, Weinstein H, Chen J and Javitch LA (1996) Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. Biochemistry 35:11278-11285.
10. Green SA, Cole G, Jacinto M, Innis M and Liggett SB (1993) A polymorphism of the human β2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116-23121.
11. 2- mobilization and clonal growth in small cell lung cancer through CCKA and CCKB/gastrin receptors. Ann NY Acad Sci 713:283-297.
12. Horwell DC (1991) Development of CCK-B antagonists. Neuropeptides 19(Suppl): 57-64.
13. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD and Woodruff GN (19901 Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732.
14. Jarnagin K, Bhakta S, Zuppan P, Yee C, Ho T, Phan T, Tahilramani R, Pease JHB, Miller A and Freedman R (1996) Mutations in the B2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists. J Biol Chem 271:28277-28286.
15. Javitch JA, Ballesteros JA, Chen J, Chiappa V and Simpson M (1999) Electrostatic and aromatic microdomains within the binding-site crevice of the dopamine D2 receptor: Contributions of the second membrane-spanning segment. Biochemistry 38:7961-7968.
16. Javitch JA, Ballesteros JA, Weinstein H and Chen J (1998) A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 37:998-1006.
17. Javitch JA, Fu D and Chen J (1995a) Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 34:16433-16439.
18. Javitch JA, Fu D, Chen J and Karlin A (1995b) Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron 14:825-831.
19. Ji H, Leung M, Zhang Y, Catt KJ and Sandberg K (1994) Differential requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor: Identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 269:16533-16536.
20. Kato T, Wang ZW, Zoega T and Crowe RR (1996) Missense mutation of the cholecystokinin B receptor gene: Lack of association with panic disorder. Am J Med Genet 67:401-405.
21. Kenakin T (1999) Efficacy in drug receptor theory: Outdated concept or under-valued tool? Trends Pharmacol Sci 20:400-405.
22. Kopin AS, McBride EW, Gordon MC, Quinn SM and Beinborn M (1997) Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. Proc Natl Acad Sci USA 94:11043-11048.
23. Kopin AS, McBride EW, Quinn SM, Kolakowski LF Jr and Beinborn M (1995) The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem 270:5019-5023.
24. Kurose H, Isogaya M, Kikkawa H and Nagao T (1998) Domains of beta1 and beta2 adrenergic receptors to bind selective agonists. Life Sci 62:1513-1517.
25. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M and Kopin AS (1997) Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112:280-286.
26. Mantamadiotis T and Baldwin GS (1994) The seventh transmembrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. Biochem Biophys Res Commun 201:1382-1389.
27. McPherson GA (1985) Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Meth 14:213-228.
28. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T and Noda T (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 93:11825-11830.
29. Pauwels PJ and Wurch T (1998) Review: Amino acids domains involved in constitutive activation of G-protein-coupled receptors. Mol Neurobiol 17:109-135.
30. Perlman S, Costa-Neto CM, Miyakawa AA, Schambye HAT, Hjorth SA, Paiva ACM, Rivero RA, Greenlee WJ and Schwartz TW (1997) Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: Susceptibility to receptor mutations. Mol Pharmacol 51:301-311.
31. Ravard S and Dourish CT (1990) Cholecystokinin and anxiety. Trends Pharmacol Sci 11:271-273.
32. Reihsaus E, Innis M, MacIntyre N and Ligget SB (1993) Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic patients. Am J Respir Cell Mol Biol 8:334-339.
33. Rim J and Oprian DD (1995) Constitutive activation of opsin: Interactions of mutants with rhodopsin kinase and arrestin. Biochemistry 34:11938-11945.
34. Ross EM (1996) Pharmacodynamics, in The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG eds) pp 29-41, McGraw-Hill, New York.
35. Sato T, Kobayashi H, Nagao T and Kurose H (1999) Ser203 as well as Ser204 and Ser207 in fifth transmembrane domain of the human beta2-adrenoreceptor contributes to agonist binding and receptor activation. Br J Pharmacol 128:272-274.
36. Schmassmann A, Garner A, Flogerzi B, Hasan MY, Sanner M, Varga L and Halter F (1994) Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut 35:270-274.
37. Schwartz TW, Gether U, Schambye HT and Hjorth SA (1995) Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharm Des 1:325-342.
38. Schwartz TW and Rosenkilde MM (1996) Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol Sci 17:213-216.
39. Silvente-Poirot S and Wank SA (1996) A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J Biol Chem 271:14698-14706.
40. Strader CD, Sigal IS and Dixon RA (1989) Genetic approaches to the determination of structure-function relationships of G protein-coupled receptors. Trends Pharmacol Sci 10 (Suppl):26-30.
41. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP and Lohse MJ (1996) Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci USA 93:9276-9281.